Ocular Therapeutix® to Host Investor Day on June 13, 2024

Core Insights - Ocular Therapeutix, Inc. will host an Investor Day on June 13, 2024, focusing on corporate strategy, clinical data, and development plans for AXPAXLI™ in treating wet AMD and NPDR [1][2] - The event will feature presentations from senior company leaders and discussions with key opinion leaders in retinal disease [2][7] - A live webcast of the presentation will be available on the company's website, with a replay accessible for at least 30 days [3] Company Overview - Ocular Therapeutix is a biopharmaceutical company dedicated to developing innovative therapies for eye diseases, including wet AMD and diabetic retinopathy [9] - AXPAXLI™ is a product candidate based on the ELUTYX™ proprietary bioresorbable hydrogel technology, currently in a Phase 3 clinical trial for wet AMD [9] - The company also has other clinical assets, including PAXTRAVA™, which is in a Phase 2 trial for open-angle glaucoma [10] Key Opinion Leaders - Baruch D. Kuppermann, MD, PhD, is a prominent figure in retinal disease research, serving as the Steinert Endowed Professor and Director of the Gavin Herbert Eye Institute at UC Irvine [4][5] - Dilsher S. Dhoot, MD, is a board-certified ophthalmologist with extensive experience in clinical research for retinal diseases [6][8] Clinical Programs - The Investor Day will provide updates on Ocular's clinical program for AXPAXLI in wet AMD, including progress on the ongoing SOL-1 study [7] - An update on Phase 1 HELIOS data for AXPAXLI in non-proliferative diabetic retinopathy (NPDR) will also be discussed [7]